Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
Diplomat Announces 3rd Quarter Financial Results
November 2, 2016 4:17 PM EDTFLINT, Mich., Nov. 2, 2016 /PRNewswire/ --Â Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation's largest independent specialty pharmacy, announced financial results for the quarter ended September 30, 2016. Â All comparisons, unless otherwise noted, are to the quarter ended September 30, 2015.
Third Quarter 2016 Highlights include:
Revenue of $1,181 million, an increase of 25% or $234 million 12% organic revenue growth Total prescriptions dispensed of 266,000, an increase of 9% Gross margin of 6.6% versus 8.0% Gross profit per prescription dispensed of $289, compared to $301... More


